AxioNovo

What AxioNovo does

AxioNovo GmbH is a privately held German pharmaceutical company headquartered in Bielefeld that develops, manufactures, and distributes a portfolio of oncology medications, including generic and branded cytotoxic agents, targeted therapies, and bone-targeted agents. Its marketed products comprise axidronat (zoledronic acid), axigran, axitaxel (paclitaxel), imatinib axios, and vinorelbin axios. The company has operated in the oncology space for over 20 years and holds GMP and GDP certifications, a Herstellungserlaubnis (manufacturing license), and a Großhandelserlaubnis (wholesale distribution license), with the most recent certifications renewed in March 2024. Its product packaging implements EU Falsified Medicines Directive serialization, including unique product codes, serial numbers, tamper-evident closures, and 2D Datamatrix codes verified against national pharmacy databases.

The company's commercial focus is the German statutory healthcare market: it distributes through pharmaceutical wholesalers to public and hospital pharmacies under rebate contracts (Rabattverträge) with statutory health insurers, and supports prescribing decisions through a dedicated HCP Fachkreise portal and patient education materials. Customer segments are oncology-treating healthcare professionals and the cancer patients they serve. Management is led by Geschäftsführer Raif Akin, with Isabell Rossa responsible for pharmacovigilance (Stufenplanbeauftragte) and Thomas Heinze as data protection officer. AxioNovo has no disclosed external funding, operates with 11–50 employees, and currently lists no open positions. The website also surfaces a Cannabis category, indicating exploratory activity beyond the core oncology franchise.

Name

AxioNovo

Legal name

AxioNovo GmbH

Website

https://www.axionovo.de

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

AxioNovo GmbH is a privately held German pharmaceutical company in Bielefeld that develops and distributes a branded generic oncology portfolio including paclitaxel, vinorelbine, imatinib, and zoledronic acid to hospitals, pharmacies, and statutory health insurers under GMP/GDP certifications.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology pharmaceuticals
• Generic drug manufacturing
• Hospital pharmaceutical supply
• Specialty oncology drugs
• EU GMP manufacturing

Headquarters

HQ city

Bielefeld

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through the sale of branded generic and proprietary oncology medications to healthcare providers, pharmacies, and indirectly to patients via prescriptions. Products include cytotoxic chemotherapy agents, targeted therapies, and bone-targeted agents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

AxioNovo GmbH is a German pharmaceutical company founded in 2004 and headquartered in Bielefeld that manufactures and distributes a portfolio of oncology pharmaceutical products including axidronat, axigran, axitaxel, imatinib axios, and vinorelbin axios. The company supplies these oncology drugs through wholesale distribution channels to pharmacies, hospitals, and healthcare professionals for the treatment of cancer patients.

Product overview

AxioNovo GmbH is a pharmaceutical company specializing in oncology with a portfolio of generic and branded cancer medications. The product portfolio includes axidronat (bisphosphonate for bone metastases), axigran, axitaxel (taxane-based), imatinib axios ( tyrosine kinase inhibitor), and vinorelbin axios (vinca alkaloid). The company operates in the oncology space with a focus on pharmaceutical products for cancer treatment, supported by anti-counterfeiting measures including serial numbers and 2D matrix codes.

Differentiator

Problem solved

Functional benefit

Products and services

• axidronat AxioNovo's oncology pharmaceutical product used in cancer treatment, distributed to pharmacies, hospitals, and healthcare professionals through wholesale channels.
• axigran AxioNovo's oncology pharmaceutical product used in cancer treatment, distributed to pharmacies, hospitals, and healthcare professionals through wholesale channels.
• axitaxel AxioNovo's oncology pharmaceutical product used in cancer treatment, distributed to pharmacies, hospitals, and healthcare professionals through wholesale channels.
• imatinib axios AxioNovo's oncology pharmaceutical product containing imatinib used in cancer treatment, distributed to pharmacies, hospitals, and healthcare professionals through wholesale channels.
• vinorelbin axios AxioNovo's oncology pharmaceutical product containing vinorelbine used in cancer treatment, distributed to pharmacies, hospitals, and healthcare professionals through wholesale channels.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• medac GmbH: Privately held German pharmaceutical company specializing in oncology, rheumatology, and urology medicines, with a similar focus on generic cytotoxic and supportive care oncology products sold through German pharmacy and hospital channels. Highly comparable in scale, German mid-market positioning, and specialty pharma business model.
• STADA Arzneimittel AG: German-headquartered generic pharmaceutical company with oncology, specialty, and consumer health products, holding German manufacturing licenses and statutory reimbursement contracts. Comparable in oncology generic portfolio and DACH distribution model, though significantly larger.
• Accord Healthcare (Intas Pharmaceuticals): Specialist generic oncology and hospital medicines company with a strong European footprint, selling injectable and oral oncology generics (including paclitaxel, imatinib, zoledronic acid) through tenders and hospital pharmacy channels. Directly comparable product overlap with AxioNovo.

Broad incumbents

• Fresenius Kabi: Global player in injectable oncology generics, IV fluids, and clinical nutrition, with extensive European manufacturing and German hospital distribution. Overlaps with AxioNovo in cytotoxic injectables (paclitaxel, vinorelbine) and supportive care (zoledronic acid, antiemetics) but operates at much greater scale.
• Sandoz (Novartis): Global generic and biosimilar leader with a substantial oncology portfolio including paclitaxel, imatinib biosimilars, and supportive care agents. Comparable in oncology generic/biosimilar strategy but operates globally with vastly greater capital, R&D, and tendering resources.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with oncology, CNS, and respiratory generics, including paclitaxel and other cytotoxic injectables. Comparable oncology generic product set and European distribution, but with global scale, biosimilar capability, and broader pipeline.
• Viatris (formerly Mylan): Global generic and specialty pharmaceutical company with significant oncology injectable and oral generics portfolios in Europe, including imatinib and zoledronic acid. Comparable in product overlap but operates across all major therapeutic areas at global scale.
• Aurobindo Pharma: India-based global generic pharmaceutical manufacturer with a strong oncology injectable and oral portfolio, including paclitaxel, imatinib, and zoledronic acid. Comparable product overlap with AxioNovo and active in European tender markets.
• Cipla Limited: Global generic pharmaceutical company with oncology, respiratory, and anti-infective portfolios, including oncology injectables and orals sold in European tender markets. Comparable in generic oncology product overlap, though much broader geographically and therapeutically.
• Hikma Pharmaceuticals: Specialty and generic pharmaceutical company with oncology injectable and oral generics, hospital-focused distribution in Europe and the Middle East. Comparable in injectable oncology generics (paclitaxel, vinorelbine) and tender-driven business model, though with broader geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AxioNovo